JMP Securities Reiterates Market Outperform Rating for OptimizeRx (NASDAQ:OPRX)

OptimizeRx (NASDAQ:OPRX)‘s stock had its “market outperform” rating reaffirmed by analysts at JMP Securities in a note issued to investors on Tuesday, Benzinga reports. They presently have a $15.00 price objective on the stock. JMP Securities’ price target would suggest a potential upside of 57.40% from the stock’s previous close.

OPRX has been the subject of a number of other research reports. Stifel Nicolaus reiterated a “buy” rating and set a $13.00 price target on shares of OptimizeRx in a research report on Monday, April 1st. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $17.00 price objective on shares of OptimizeRx in a report on Monday, April 1st. Finally, Barclays began coverage on shares of OptimizeRx in a research note on Wednesday, January 3rd. They set an “equal weight” rating and a $15.00 target price on the stock. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, OptimizeRx presently has a consensus rating of “Moderate Buy” and an average target price of $15.86.

OptimizeRx Trading Down 4.3 %

Shares of NASDAQ OPRX opened at $9.53 on Tuesday. OptimizeRx has a 12-month low of $6.92 and a 12-month high of $16.65. The company has a market cap of $172.97 million, a PE ratio of -11.91 and a beta of 0.98. The stock has a 50 day simple moving average of $13.48 and a 200-day simple moving average of $11.97.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. JPMorgan Chase & Co. raised its position in OptimizeRx by 17.0% in the first quarter. JPMorgan Chase & Co. now owns 13,235 shares of the company’s stock worth $499,000 after acquiring an additional 1,920 shares in the last quarter. Raymond James & Associates raised its holdings in shares of OptimizeRx by 21.1% in the 1st quarter. Raymond James & Associates now owns 12,116 shares of the company’s stock worth $457,000 after purchasing an additional 2,111 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in OptimizeRx by 8.3% during the first quarter. Bank of New York Mellon Corp now owns 178,630 shares of the company’s stock valued at $6,735,000 after purchasing an additional 13,725 shares during the last quarter. MetLife Investment Management LLC boosted its holdings in OptimizeRx by 58.3% during the first quarter. MetLife Investment Management LLC now owns 9,158 shares of the company’s stock worth $345,000 after buying an additional 3,371 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in OptimizeRx by 12.8% during the first quarter. Rhumbline Advisers now owns 42,886 shares of the company’s stock worth $1,617,000 after buying an additional 4,878 shares in the last quarter. Institutional investors own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow.